Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HRS-7535
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Bain Capital Life Sciences
Deal Size : $400.0 million
Deal Type : Financing
Investors put $400M into Biotech Licensing Obesity Drugs from China
Details : The financing aims to fund the development of HRS-7535, a novel, oral small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist, being developed for the treatment type 2 diabetes and obesity.
Product Name : HRS-7535
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 16, 2024
Lead Product(s) : HRS-7535
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Bain Capital Life Sciences
Deal Size : $400.0 million
Deal Type : Financing
Lead Product(s) : HP163
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hercules' AHR Inhibitor Hp163 Blocks Viral Replicationinn Zika Infection and Potentially in Covid-19
Details : A recent publication in Nature Neuroscience reported that Hercules’ AhR inhibitor HP163 reduces viral replication in animals infected with Zika-virus and reduced microencephaly.
Product Name : HP163
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 20, 2020
Lead Product(s) : HP163
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
